Prostate Cancer: Rising Cases, Screening Debate & Men’s Health Stories

Almost seven years into retirement, David Bulteel should be enjoying the fruits of a 40-year career in the City. He has a tidy pension, delightful grandchildren, and a home in Buckinghamshire. But for the past 13 years, a prostate cancer diagnosis has cast a shadow over his life, impacting not only his own wellbeing but also that of his entire family. His story, and those of others like him, underscore a growing public health challenge: prostate cancer is now the most commonly diagnosed cancer in the UK, with diagnoses reaching nearly 65,000 in 2022, surpassing even breast cancer cases.

The Rising Tide of Prostate Cancer Diagnoses

The increase in prostate cancer diagnoses isn’t necessarily a sign that the disease is becoming more prevalent, but rather a reflection of increased awareness, improved screening practices, and a willingness among men to discuss their health. High-profile figures like the late BBC news presenter Bill Turnbull and champion cyclist Sir Chris Hoy publicly sharing their experiences have undoubtedly played a role in destigmatizing the disease and encouraging men to seek testing. However, this rise also highlights disparities in access to care and the ongoing debate surrounding widespread screening programs.

Prostate cancer develops in the prostate gland, a walnut-sized organ that contributes to semen production and urinary control. Symptoms can include changes in urination patterns, erectile dysfunction, lower back pain, and unexplained weight loss. However, many men experience no symptoms in the early stages, making regular check-ups and awareness of risk factors crucial. These risk factors include age, family history, and ethnicity – Black men are understood to be twice as likely to develop prostate cancer as men of other ethnicities, though the genetic basis for this disparity is still being investigated.

The PSA Test: A Double-Edged Sword

David Bulteel’s diagnosis came about through a routine health check offered by his employer, which included a blood test for prostate-specific antigen (PSA). PSA is a protein produced by cells in the prostate, and elevated levels can indicate the presence of cancer. However, the PSA test is not foolproof. It can yield false positives, leading to unnecessary anxiety and invasive biopsies, or false negatives, potentially delaying diagnosis. As Cancer Research UK explains, of every 1,000 men aged 50-60 screened with a PSA test, around 20 could be overdiagnosed and subjected to treatments they may not need.

This inherent imprecision is a key reason why the UK National Screening Committee recently decided against a comprehensive, nationwide prostate cancer screening program. While targeted screening for men with a BRCA1 or BRCA2 gene variant – which increases cancer risk – is being considered, a broader rollout remains contentious. Prostate Cancer UK continues to advocate for expanded screening, particularly for at-risk groups, arguing that the potential benefits outweigh the harms.

Disparities in Access and the Impact of Socioeconomic Factors

Beyond the limitations of the PSA test, socioeconomic inequalities are exacerbating the problem. Prostate Cancer UK has found that individuals living in more deprived areas are 29% more likely to be diagnosed with advanced prostate cancer compared to those in wealthier areas. This suggests that access to timely testing and quality healthcare is not equitable, leaving vulnerable populations at greater risk.

Martin Walsh, a retired purchasing manager, regrets not getting tested earlier despite knowing his family history. He only sought a PSA test after experiencing pelvic pain and frequent nighttime urination. Similarly, Junior Hemans, a management consultant and mental health advocate, proactively requested a PSA test at age 50, aware of the increased risk among Black men. Both men benefited from early detection and treatment, but their experiences highlight the importance of proactive screening and awareness, particularly within at-risk communities.

Treatment and Living with the Long-Term Effects

Prostate cancer treatment options vary depending on the stage and aggressiveness of the disease. They can include surgery, radiotherapy, hormone therapy, and, in some cases, chemotherapy. However, these treatments often come with significant side effects, including heart problems, bladder issues, erectile dysfunction, and depression. David Bulteel’s experience exemplifies the long-term challenges faced by many men living with prostate cancer. His ongoing hormone therapy, while controlling the disease, has impacted his energy levels, libido, and overall quality of life.

Phil Pennington, a Merseyside police officer, underwent surgery and radiotherapy after his diagnosis. While his PSA levels are now low and his doctors are optimistic, he continues to grapple with the emotional toll of the experience, particularly the fear of recurrence and the impact on his family. The emotional and psychological support available to men diagnosed with prostate cancer is therefore as crucial as the medical treatment itself.

What’s on the Horizon for Prostate Cancer Care?

The UK National Screening Committee is currently reviewing its prostate cancer screening policy, with a consultation period concluding this month. The outcome of this review, along with considerations for the cost implications for the NHS, will shape the future of prostate cancer screening in the UK. In the meantime, organizations like Prostate Cancer UK are working to raise awareness, advocate for equitable access to care, and fund research into more effective diagnostic and treatment methods.

For men concerned about their risk of prostate cancer, the advice remains consistent: talk to your doctor about your individual risk factors and whether a PSA test is appropriate for you. Early detection and proactive management are key to improving outcomes and ensuring that men can live long and fulfilling lives, even in the shadow of this increasingly common disease.